Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04034459
Title FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC (AIO-KRK-0116)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Ludwig-Maximilians - University of Munich
Indications

colon adenocarcinoma

rectum adenocarcinoma

colorectal cancer

Therapies

Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin

Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin

Age Groups: adult | senior
Covered Countries DEU

Additional content available in CKB BOOST